Pelthos Therapeutics Inc (PTHS) Stock Analysis

AI analysis of Pelthos Therapeutics Inc (PTHS)

Hold

Pelthos Therapeutics Inc is not a strong buy at the moment due to its current price of $11.52, which is significantly below its 52-week high of $37.50. The RSI is at 31.083, indicating that the stock is oversold, but the recent performance shows a 5-day change of -24.21% and a year-to-date change of -60.88%. While there are positive catalysts such as revenue growth to $10.7 million in Q1 2026 and a strategic merger with Castle Creek, the company still faces significant financial challenges, including a net loss of $10.2 million in Q1 and a forward P/E ratio of 0, suggesting uncertainty in profitability. The main risk is the high volatility in prescription trends for its lead product ZELSUVMI, which analysts have noted as flat. Therefore, while there may be potential for recovery, the current financial instability and market conditions suggest a cautious approach.

Valuation Metrics

The current forward P/E ratio for Pelthos Therapeutics Inc (PTHS) is 0.00, compared to its 5-year average forward P/E of -7.52.

Forward P/E

Overvalued

5Y Average P/E

-7.52

Current P/E

0.00

Overvalued

-2.80

Undervalued

-12.25

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-1.03

Current EV/EBITDA

-0.81

Overvalued

0.01

Undervalued

-2.07

Forward P/S

Fair

5Y Average P/S

1.33

Current P/S

0.34

Overvalued

2.65

Undervalued

0.01

Alphio AI Price Scenarios for PTHS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%PTHS

$26.27

Scenario price

B

Base

Base · 50%PTHS

$23.56

Scenario price

B

Bear

Bear · 25%PTHS

$23.29

Scenario price

PTHS FAQ — answered by Alphio AI

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older. It operates in the Healthcare sector.

Pelthos Therapeutics Inc is not a strong buy at the moment due to its current price of $11.52, which is significantly below its 52-week high of $37.50. The RSI is at 31.083, indicating that the stock is oversold, but the recent performance shows a 5-day change of -24.21% and a year-to-date change of -60.88%. While there are positive catalysts such as revenue growth to $10.7 million in Q1 2026 and a strategic merger with Castle Creek, the company still faces significant financial challenges, including a net loss of $10.2 million in Q1 and a forward P/E ratio of 0, suggesting uncertainty in profitability. The main risk is the high volatility in prescription trends for its lead product ZELSUVMI, which analysts have noted as flat. Therefore, while there may be potential for recovery, the current financial instability and market conditions suggest a cautious approach.